These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36777363)

  • 1. Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
    Teresa VD; Rául OM; Marisa I; Claudia HG; Esteban FV; Luigi M; Mª Mar MR; Lilyan KC; Luisa CP; Ángel PD; Raquel VL; Noemí MM; Benito VJ; Marta LS; Beatriz LC; Francisco MG; Pau GÁ; Federico AA
    Therap Adv Gastroenterol; 2023; 16():17562848231153560. PubMed ID: 36777363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
    Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
    BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term real-world data of ustekinumab in Crohn's disease: the Stockholm ustekinumab study.
    Bello F; Muhsen S; Sabhan H; Borin A; Johansson F; Höög C; Forsberg O; Wennerström C; Söderman C; Lördal M; Almer S
    Therap Adv Gastroenterol; 2024; 17():17562848241242700. PubMed ID: 38655034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.
    Inniss S; Fragkos KC; Whitley L; Wimpory R; Rebello E; Lisboa A; Khetan T; Hassan J; Simpson K; Bhagwanani A; Vega R; Parisi I; Harrow P; Seward E; McCartney S; Bloom S; Smith AM; Plumb A; Rahman FZ
    Ther Adv Chronic Dis; 2023; 14():20406223231189072. PubMed ID: 37601038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
    Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
    Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN.
    Pujol-Muncunill G; Navas-López VM; Ledder O; Cohen S; Lekar M; Turner D; Kolho KL; Levine A; Croft NM; Bronsky J; Shouval DS; Assa A; Harris R; Kiparissi F; Aloi M; Afzal NA; Tzivinikos C; Barrio J; Norden C; Vega MJB; Buderus S; de Valderrama AF; de Ridder L; García-Romero R; Medina E; Sánchez C; Velasco M; Vicente S; Wilson DC; Naik S; Hradsky O; Cococcioni L; Martin-de-Carpi J
    Eur J Pediatr; 2024 Aug; 183(8):3253-3262. PubMed ID: 38700692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
    Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
    Scribano ML; Aratari A; Neri B; Bezzio C; Balestrieri P; Baccolini V; Falasco G; Camastra C; Pantanella P; Monterubbianesi R; Tullio A; Saibeni S; Papi C; Biancone L; Cosintino R; Faggiani R
    Therap Adv Gastroenterol; 2022; 15():17562848211072412. PubMed ID: 35186121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    Straatmijer T; Biemans VBC; Hoentjen F; de Boer NKH; Bodelier AGL; Dijkstra G; van Dop WA; Haans JJL; Jansen JM; Maljaars PWJ; van der Marel S; Oldenburg B; Ponsioen CY; Visschedijk MC; de Vries AC; West RL; van der Woude CJ; Pierik M; Duijvestein M; van der Meulen-de Jong AE
    J Crohns Colitis; 2021 Nov; 15(11):1920-1930. PubMed ID: 33909062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.
    Monin L; Dubois S; Reenaers C; Van Kemseke C; Latour P; Van Daele D; Vieujean S; Seidel L; Louis E
    Dig Liver Dis; 2021 Jan; 53(1):72-78. PubMed ID: 33221330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
    Zhdanava M; Ding Z; Manceur AM; Zhao R; Holiday C; Kachroo S; Izanec J; Pilon D
    Curr Med Res Opin; 2023 Sep; 39(9):1215-1225. PubMed ID: 37563994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study.
    Bessissow T; Narula N; Ma C; In TSH; Eberg M; Karra K; Jairath V;
    Dig Liver Dis; 2024 Jan; 56(1):61-69. PubMed ID: 37716860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
    Lee CK; Moon W; Chun J; Kim ES; Kim HW; Yoon H; Kim HS; Lee YJ; Choi CH; Jung Y; Park SC; Song GA; Lee JH; Jung ES; Kim Y; Jung SY; Choi JM; Ye BD
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39096895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.